Could dropping aspirin after a heart attack be safer?

NCT ID NCT07257198

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking only the blood thinner ticagrelor (instead of the usual combination of ticagrelor plus aspirin) can reduce bleeding after a heart attack. It involves 2,570 adults who had a heart attack but did not receive stents or bypass surgery. Participants will take either ticagrelor plus a placebo or ticagrelor plus aspirin for 12 months, and researchers will compare bleeding events and major heart problems between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ticagrelor (a blood thinner) plus a placebo, compared to ticagrelor plus aspirin

What this could lead to

If successful, this could show that using only ticagrelor after a heart attack lowers bleeding risk while still preventing future heart problems, leading to a safer treatment option.

What could go wrong

This is a large Phase 3 trial, but it only includes patients who did not receive stents or bypass surgery, so results may not apply to everyone. There is still a risk that ticagrelor alone may not prevent heart attacks or strokes as well as the standard combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction Hemorrhage myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, H1Y2P3, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••